Triamcinolone


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Severe psoriasis, Dermatitis herpetiformis, Allergic and inflammatory conditions of the eye, Idiopathic thrombocytopenic purpura, Crohn's disease, Allergic conditions, Congenital adrenal hyperplasia, Hypercalcaemia of malignancy, Mycosis fungoides, Systemic lupus erythematosus, Primary adrenocortical insufficiency, Secondary adrenocortical insufficiency, Non-suppurative thyroiditis, Adjunctive therapy in rheumatic disorders, Acute rheumatic heart disease, Pemphigus, Erythema multiforme, Exfoliative dermatitis, Loffler's syndrome, Berylliosis, Fulminant pulmonary tuberculosis, Intractable sprue, Palliative treatment of lymphoma, Palliative treatment of leukaemia, Congenital hypoplastic anaemia, Erythroblastopaenia, Secondary thrombocytopenia, Acquired haemolytic anaemia, Diffuse interstitial pulmonary fibrosis, Pulmonary emphysema, Symptomatic sarcoidosis, Ulcerative colitis, Disseminated pulmonary tuberculosis
Adult: Initially, 4-48 mg daily depending on the disease being treated; may be maintained or adjusted until a satisfactory response is noted.
Child: Dosing is based on the disease entity being treated.
Administration
Should be taken with food.
Contraindications
Idiopathic thrombocytopenic purpura, cerebral malaria; untreated fungal, viral, or bacterial infections; acute psychosis, active TB, herpes simplex keratitis, systemic mycosis and parasitosis.
Special Precautions
Patient with glaucoma and/or cataracts, hypertension and/or heart failure, acute MI, diabetes mellitus, gastrointestinal diseases (intestinal anastomoses, diverticulitis, peptic ulcer, ulcerative colitis), cirrhosis, myasthenia gravis, osteoporosis, history of seizure disorder. Avoid abrupt withdrawal. Children. Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor growth and development of child on prolonged therapy.
Adverse Reactions
Significant: Adrenal suppression, immunosuppression (e.g. secondary infections, superinfections); kaposi sarcoma, myopathy, psychiatric disturbances including insomnia and depression (parenteral); local topical, nasal or ocular effects (e.g. sensitization, visual disturbances such as increased intraocular pressure, endophthalmitis). Eye disorders: Cataract (ocular). Gastrointestinal disorders: Dyspepsia, tooth disorder (nasal). Injury, poisoning and procedural complications: Injection site reactions (e.g. blurring of vision for ocular, discomfort, pain, erythema, swelling, necrosis, abscess). Investigations: Elevated blood pressure, weight gain (parenteral). Metabolism and nutrition disorders: Increased appetite, fluid retention, glucose tolerance alteration (parenteral). Musculoskeletal and connective tissue disorders: Arthralgia (parenteral). Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Epistaxis (nasal).
Potentially Fatal: Rarely, anaphylaxis.
ROUTE(S) : IB / Intradermal / Intrasynovial / SC / Topical / Intra-articular / Intralesional / IM / Parenteral: C
ROUTE(S) : Intravitreal: D
Drug Interactions
May antagonise effect of anticholinesterase agent. Additional increase of intraocular pressure with anticholinergics (e.g. atropine). May potentiate or reduce anticoagulant effect of oral anticoagulants. May increase hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of antidiabetics (e.g. sulfonylurea derivatives) and insulin. May diminish arterial blood pressure reduction of antihypertensives (including diuretics). May reduce isoniazid serum concentrations. Increase in both ciclosporin and corticosteroids activity when used concomitantly. May increase toxicity of digitalis glycosides. Increased effects with ketoconazole. May alter the neuromuscular blocking action of non-depolarising muscle relaxants. May increase risk of gastrointestinal bleeding and ulceration associated with NSAIDs. Increased serum levels with oestrogen (including oral contraceptives). Neurological complications and diminished antibody response may occur on vaccinated patients. May develop hypokalaemia with K-depleting agents (e.g. amphotericin B inj, diuretics). May increase risk of QT prolongation or torsade de pointes with class Ia antiarrhythmics (e.g. disopyramide, quinidine, procainamide) or class II antiarrhythmics (e.g. amiodarone, sotalol, bepridil).
Lab Interference
May produce false-negative results with nitroblue tetrazolium test for bacterial infection. May produce a positive result in anti-doping test for athletes. May suppress reactions to skin tests.
Action
Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation. It also suppresses the immune system by reducing activity and volume of the lymphatic system.
Absorption: Slowly absorbed from inj sites. Time to peak plasma concentration: 8-10 hours (IM).
Distribution: It crosses the placenta. Volume of distribution: 99.5 L. Plasma protein binding: Approx 68%.
Excretion: Via urine (approx 40%); faeces (approx 60%). Plasma half-life: Approx 2-5 hours.
Storage
Oral: Store between 20-25°C. Do not freeze. Protect from light.
CIMS Class
Corticosteroid Hormones / Eye Corticosteroids / Mouth/Throat Preparations / Topical Corticosteroids
ATC Classification
R03BA06 - triamcinolone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
R01AD11 - triamcinolone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
D07XB02 - triamcinolone ; Belongs to the class of moderately potent (group II) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
C05AA12 - triamcinolone ; Belongs to the class of products containing corticosteroids for topical use. Used in the treatment of hemorrhoids and anal fissures.
A01AC01 - triamcinolone ; Belongs to the class of local corticosteroid preparations. Used in the treatment of diseases of the mouth.
D07AB09 - triamcinolone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
S01BA05 - triamcinolone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
Disclaimer: This information is independently developed by CIMS based on triamcinolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in